Pharmaceuticals
Bad News Beset This Biotech, but I See a Boost Ahead
TG Therapeutics could see a win with its multiple sclerosis therapy -- and I've got a lesson for traders staying nimble.
Neurocrine Biosciences Looks Promising: Here's Our Trading Strategy
The shares are trading above the rising 40-week moving average line.
I Don't Trust CVS Health's Stock: Here's When I Get Out
I have no patience moving forward with a large firm standing on a sloppy book, trying to digest an acquisition it needs to make, but can only questionably afford.
A Technical Strategy to 'Buy' Agios Pharmaceuticals
Here's what aggressive traders could do now.
AstraZeneca Looks Vulnerable
Here's what investors should do now.
Supernus Pharmaceuticals Appears Ready for an Upside Breakout
The charts of the biopharmaceutical company are flashing bullish signals.
This Small-Cap Cancer Technology Company Could Pop With the Right Play
Let's look at a strategy for Cardiff Oncology, whose shares got snagged in the biotech selloff in early 2022.
This Cancer Therapy Company Is Small but Its 'Options' Look Big
Here's how to play this small-cap biotech that's targeting a type of kidney-related cancer.
Drugmakers Have No Magic Pill for Today, but They Do Inject Some Hope
Here's a play in Pfizer.
2 Stocks That Should Perform Well Even if Consumers Pull In Their Horns
There are reasons to be optimistic about Hims & Hers Health and OptiNose Inc.